These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29261796)

  • 1. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
    Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
    PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
    Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
    Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
    Fishman M; Dutcher JP; Clark JI; Alva A; Miletello GP; Curti B; Agarwal N; Hauke R; Mahoney KM; Moon H; Treisman J; Tykodi SS; Daniels G; Morse MA; Wong MKK; Kaufman H; Gregory N; McDermott DF
    J Immunother Cancer; 2019 Mar; 7(1):84. PubMed ID: 30917871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
    Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
    Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
    Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
    J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
    Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
    J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma.
    Gu L; Li H; Wang H; Ma X; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):499-508. PubMed ID: 27844145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
    Molina AM; Lin X; Korytowsky B; Matczak E; Lechuga MJ; Wiltshire R; Motzer RJ
    Eur J Cancer; 2014 Jan; 50(2):351-8. PubMed ID: 24051327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation.
    Adibi M; Thomas AZ; Borregales LD; Merrill MM; Slack RS; Chen HC; Sircar K; Murugan P; Tamboli P; Jonasch E; Tannir NM; Matin SF; Wood CG; Karam JA
    Urol Oncol; 2015 Oct; 33(10):427.e17-23. PubMed ID: 26004164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
    Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
    Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.
    Pal SK; Jones JO; Carmichael C; Saikia J; Hsu J; Liu X; Figlin RA; Twardowski P; Lau C
    Urol Oncol; 2013 Nov; 31(8):1826-31. PubMed ID: 22608544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.
    Kuzman JA; Stenehjem DD; Merriman J; Agarwal AM; Patel SB; Hahn AW; Alex A; Albertson D; Gill DM; Agarwal N
    BMC Urol; 2017 Jan; 17(1):1. PubMed ID: 28056941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.
    Mian BM; Bhadkamkar N; Slaton JW; Pisters PW; Daliani D; Swanson DA; Pisters LL
    J Urol; 2002 Jan; 167(1):65-70. PubMed ID: 11743277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.